Abstract Details

Title Multiple Sclerosis Treatment Decisions: EDSS Independent Disease Impact/Reserve and the Use of Additional Milestones that Matter

Topic Multiple Sclerosis

Presentation(s) P4 - (-)

Poster/Presentation
Number 392

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Daniel Golan, MD (Carmel Medical Center) PRESENTER	No disclosure on file
Mark Gudesblatt, MD (South Shore Neurology Assoc. PC)	The institution of Dr. Gudesblatt has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for genentech. The institution of Dr. Gudesblatt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
	No disclosure on file
Myassar Zarif	Myassar Zarif has nothing to disclose.
Barbara Bumstead, NP	Ms. Bumstead has nothing to disclose.
	No disclosure on file
Jared Srinivasan	No disclosure on file
Ilir Topalli	No disclosure on file
Jeffrey A. Wilken, PhD (NAF)	No disclosure on file
Karen Blitz-Shabbir, DO	No disclosure on file
Marijean Buhse (Stony Brook University)	Marijean Buhse has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.
Glen M. Doniger, PhD (NeuroTrax Israel Ltd.)	No disclosure on file

��ɫ��